Bristol Myers Squibb at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Bristol Myers Squibb takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on irafamdastat, a dual FAAH and MAGL inhibitor, and how it changes the endocannabinoid system in people. Its work reports phase 1 results in healthy adults.
| Organization | CTAD 2026 Attendance |
|---|---|
Bristol Myers Squibb Princeton, New Jersey | ◆Gold Sponsor |
Global drugmaker testing Cobenfy for psychosis in Alzheimer's disease and developing an anti-tau antibody, among other neuroscience programs. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue |
Instantly find 20 buyers from Bristol Myers Squibb
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction